Valneva SE Valneva (NASDAQ: VALN) Confirms EMA Accepts Filing of MAA for Inactivated COVID-19 Vaccine Candidate Valneva SE (NASDAQ: VALN) announced that the European Medicines Agency (EMA) has approved Valneva's inactivated, whole-virus COVID-19 vaccine candidate, VLA2001, for marketing authorization. With the acceptance of the MAA, VLA2001
Valneva SE Valneva (NASDAQ: VALN) Confirm EC to Terminate COVID-19 Vaccine Purchase Agreement Valneva SE (NASDAQ: VALN) confirmed that the European Commission (EC) has given notice of its intention to terminate the advance purchase agreement (APA) for Valneva's inactivated whole-virus COVID-19 vaccine candidate
